BoswelliaBotanical

• Knee osteoarthritisLikely helps

  This is the one use with repeated meta-analytic support behind it.
  
  A 2018 systematic review and meta-analysis of 11 RCTs (N=1,009) found boswellia formulations statistically significantly better than placebo for knee osteoarthritis pain and function, with safety outcomes no different from placebo [7].
  
  A 2020 systematic review and meta-analysis reached a similar conclusion, recommending at least 4 weeks of use at the 100–250 mg doses it pooled — while rating the included study quality medium to low [5]. A 2024 sub-group meta-analysis found the standardized extract Aflapin significantly effective against comparators [6].
  
  No RCT in the 2018 review compared boswellia directly against an NSAID, so that comparison is simply unmade [7]. ^[7]

• How to read those positive trialsPossibly helps

  Two things are true at once here, and skipping either one distorts the picture.
  
  NCCIH's overall stance is that there is not enough high-quality evidence to confirm boswellia for any single condition [1].
  
  Individual trials of branded extracts — Aflapin, 5-Loxin, Boswellin Super — report statistically significant benefits, and several are industry-funded [6][10]. A positive trial existing and a cumulative evidence base still judged low-to-medium quality are compatible, not contradictory. ^[1]

• Ulcerative colitis and Crohn's diseasePossibly helps

  The bowel evidence splits by trial size and duration, and the bigger trial is the negative one.
  
  Small RCTs found gum resin comparable to sulfasalazine for ulcerative colitis and chronic colitis remission, and non-inferior to mesalazine in active Crohn's over 8 weeks [3].
  
  A 52-week placebo-controlled trial in 82 Crohn's patients found boswellia well tolerated but no better than placebo at maintaining remission, at 60% against 55% [8].
  
  Short positive trials against a long null one is a familiar pattern, and it is not resolved here [3][8]. ^[8]

• Collagenous colitisNot shown to help

  A systematic review of 10 RCTs concluded that Boswellia serrata extract was ineffective for collagenous colitis specifically [12].
  
  That is a stronger negative than 'unproven' — it is the one place on this page where pooled trial evidence points at no effect [12]. ^[12]

• AsthmaPossibly helps

  In a double-blind placebo-controlled 6-week trial of 80 adults with bronchial asthma, boswellia gum resin at 300 mg three times daily produced greater improvement than placebo [3]. Nearly everyone in both groups improved, which complicates the reading.
  
  NCCIH's summary is that a few small studies suggest a benefit, but the evidence is not rigorous enough to confirm it [1]. ^[3]

• Rheumatoid arthritisPossibly helps

  Largely negative on the disease's own outcome measures.
  
  A placebo-controlled trial of 78 outpatients at 3,600 mg/day found NSAID use fell further in the boswellia group (5.8%) than on placebo (3.1%) [13]. No other significant benefit was observed.
  
  This is one trial, so it is thin in both directions rather than a settled negative [13]. ^[13]

• Blood sugar and lipids in diabetesPossibly helps

  A double-blind RCT of 56 patients with diabetes added 500 mg/day of boswellia to standard antidiabetic therapy for 8 weeks [13].
  
  Glucose and lipid results were no better than placebo [13]. Again, a single trial rather than a body of evidence. ^[13]

• Brain swelling after radiotherapyPossibly helps

  A more rigorously studied use than the supplement-aisle framing suggests.
  
  A prospective, randomized, placebo-controlled, double-blind pilot trial in patients irradiated for brain tumours found boswellia acted on cerebral oedema [19]. A related smaller study suggested an effect on the oedema but not the underlying tumour in malignant glioma.
  
  NCCIH lists this among boswellia's more encouraging areas, while still calling the evidence limited [1]. Topical boswellia creams have separately been tested in randomized placebo-controlled trials for radiation-induced skin damage during breast cancer radiotherapy [14]. ^[19]

• Crude gum-resin extractThe form behind most of the older ulcerative colitis, Crohn's and asthma research .

  Elemental content

  Unstandardized, or labelled by total boswellic acid percentage rather than AKBA

  Absorption

  Dosed 250–500 mg two to three times daily in most trials, roughly 600–1,500 mg/day [3]

  Best for

  The form behind most of the older ulcerative colitis, Crohn's and asthma research [3].
  
  It is also the form most likely to be sold with a vague or absent standardization figure.

• 5-LoxinShowing why milligrams alone mislead — 100 mg here is not 100 mg of crude extract .

  Elemental content

  Standardized to 30% AKBA [12]

  Absorption

  Osteoarthritis benefit reported at doses as low as 100 mg/day [12]

  Best for

  Showing why milligrams alone mislead — 100 mg here is not 100 mg of crude extract [12].
  
  It has been outperformed by Aflapin at a comparable dose in one trial [15].

• AflapinThe form singled out by a 2024 sub-group meta-analysis as significantly effective against comparators .

  Elemental content

  Boswellia serrata extract combined with non-volatile oil fractions

  Absorption

  Higher oral AKBA bioavailability than 5-Loxin in clinical study [15]

  Best for

  The form singled out by a 2024 sub-group meta-analysis as significantly effective against comparators [6].
  
  Worth noting that much of its trial record is manufacturer-linked [6].

• Enhanced-delivery formulationsWokVida outperformed a standardized extract in one osteoarthritis trial .

  Elemental content

  Solid lipid particles (WokVida) or lecithin-based carriers (Casperome)

  Absorption

  Designed around boswellic acids' inherently poor oral bioavailability [9]

  Best for

  WokVida outperformed a standardized extract in one osteoarthritis trial [15].
  
  The category is newer and thinner on independent replication than the AKBA extracts.

• Raw, unprocessed bark powderNothing. A man who ingested it developed acute interstitial nephritis, confirmed on biopsy, and needed two haemodialysi…

  Elemental content

  A traditional preparation from a different plant part — not the purified gum resin

  Absorption

  Not characterised in any trial here

  Best for

  Nothing. A man who ingested it developed acute interstitial nephritis, confirmed on biopsy, and needed two haemodialysis sessions [18].
  
  Infrared spectroscopy found calcium oxalate crystals in the bark powder that were absent from purified gum resin [18]. The commercial extract and the raw bark are not the same product.

• Topical cream or frankincense oilRadiation dermatitis trials used a topical boswellia cream .

  Elemental content

  Resin extract in a cream base, or the essential oil

  Absorption

  Not established for systemic effect

  Best for

  Radiation dermatitis trials used a topical boswellia cream [14].
  
  NCCIH states there is not enough evidence that topical use works for osteoarthritis, rheumatoid arthritis or other conditions [1].

• Stomach upset and heartburn

  This is the most commonly reported category, and it is generally mild and transient.
  
  Stomach pain, heartburn, nausea, diarrhoea, headache and general weakness lead the list [1][2]. Several controlled trials found these occurred at rates similar to placebo [3]. ^[2]

• Autoimmune conditions

  The same pharmacy reference advises people with multiple sclerosis, lupus or rheumatoid arthritis to avoid boswellia [2].
  
  The stated reason is that it might increase immune system activity and worsen symptoms [2]. ^[2]

• Liver — reassuring, with one caveat

  NIH's LiverTox reviewed the published literature, including US and international drug-induced-liver-injury and acute-liver-failure registries, and found no convincing case of clinically apparent liver injury from Boswellia serrata extract [3].
  
  It carries LiverTox's most reassuring category, likelihood score E [3]. Small trials showed no meaningful ALT elevations against placebo.
  
  The caveat is that boswellia often appears in multi-ingredient products, some of which have been implicated in liver injury without any specific boswellia contribution being established [3]. ^[3]

• High-dose toxicity

  A 2024 case report documented SIADH, severe hyponatraemia, a generalised tonic-clonic seizure and rhabdomyolysis [16].
  
  The patient had self-escalated to 1,000 mg/day for three weeks, and fully recovered after stopping [16]. Dose escalation beyond studied ranges is the identified risk factor. ^[16]

• Kidney injury — depends on the form

  The standard commercial gum-resin extract used in almost all trials has not been linked to kidney injury in controlled studies [17].
  
  Outside that pattern, two real signals exist. A 2026 report found possible acute kidney injury when boswellia was used at high doses for radiation necrosis [17].
  
  Separately, a man who ingested raw unprocessed bark powder developed acute interstitial nephritis, confirmed on biopsy [18]. He needed haemodialysis before recovering over 3 weeks on steroids.
  
  Calcium oxalate crystals were found in that bark powder and not in the purified resin [18].
  
  So this is not one verdict: dose and preparation decide which risk applies [17][18]. ^[17]

• Children

  Paediatric data is essentially absent — boswellia has been studied almost entirely in adults [1][2].
  
  Neither NCCIH nor the professional references reviewed give a paediatric dose or safety profile [1]. Extrapolating down from adult dosing is not supported by anything here. ^[1]

• Breastfeeding

  NCCIH says boswellia is likely safe in the amounts found in foods while breastfeeding [1].
  
  That is a thin reassurance, since boswellia is not present in food in any meaningful amount. Little is known about supplement-dose boswellia or frankincense during breastfeeding [1]. ^[1]

• CYP450-metabolised medications

  A professional pharmacy reference rates this moderate, meaning caution and a conversation with the prescriber [2].
  
  Boswellia may inhibit CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 — the enzymes handling a wide swathe of common drugs [2].
  
  Named examples include several antidepressants, antipsychotics, benzodiazepines, some proton pump inhibitors, phenytoin, and blood-pressure drugs such as losartan, irbesartan and propranolol [2].
  
  This is an enzyme-based mechanism rather than a documented clinical event, which is a reason for caution rather than reassurance [2]. ^[2]

• Warfarin

  Warfarin is metabolised by CYP2C9, one of the enzymes boswellia may inhibit, so the same moderate rating applies [2].
  
  No dedicated trial testing a real-world bleeding interaction was found [2]. Anyone on an anticoagulant should read this as plausible and unresolved rather than ruled out. ^[2]

None. Boswellia is a tree gum resin, not a food, and it does not appear in an ordinary diet in any meaningful amount.

It reaches people through supplement capsules and tablets, or topically and by inhalation as frankincense oil or cream.

That matters for one specific claim: 'likely safe in amounts found in foods' is a near-empty statement for a substance that food does not contain [1].

With food, and ideally with fat in it. This is one of the few timing answers on this site backed by a direct pharmacokinetic comparison.

A randomized, open-label, single-dose crossover study in healthy male volunteers compared a gum-resin extract fed against fasted [11].

With a standardized high-fat meal, peak plasma concentrations and total absorption of beta-boswellic acid, KBA and AKBA were several-fold higher than in the fasted state [11].

Two further boswellic acids — alpha-boswellic acid and its acetyl form — were only detectable in plasma at all when taken with food [11].

Most trials dosed two to three times daily, generally around meals [3]. No study compared morning against evening, so nothing supports a particular hour beyond the food effect itself.